Cargando…

Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis

OBJECTIVE: Multiple sclerosis (MS) prevalence, clinical patterns, and treatment responses vary between races and geographical latitudes. Glatiramer acetate (GA; Copaxone) has provided a safe, effective treatment option for relapsing–remitting MS patients in the USA, European nations, and other count...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamura, Takashi, Ashtamker, Natalia, Ladkani, David, Fukazawa, Toshiyuki, Houzen, Hideki, Tanaka, Masami, Miura, Toshiro, Knappertz, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	MS/NMO and allied disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485168/ https://www.ncbi.nlm.nih.gov/pubmed/28706565 http://dx.doi.org/10.1111/cen3.12383

Ejemplares similares

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database
por: Ogino, Mieko, et al.
Publicado: (2016)

Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database
por: Ogino, Mieko, et al.
Publicado: (2017)

Neurological safety of fingolimod: An updated review
por: Yoshii, Fumihito, et al.
Publicado: (2017)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
por: Rieckmann, Peter, et al.
Publicado: (2021)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
por: Rovituso, Damiano M., et al.
Publicado: (2015)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
por: Zivadinov, Robert, et al.
Publicado: (2015)

Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis
por: Criscuolo, C., et al.
Publicado: (2019)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study()
por: Abolfazli, Roya, et al.
Publicado: (2018)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
por: Melendez-Torres, G. J., et al.
Publicado: (2018)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study
por: Jongen, Peter J, et al.
Publicado: (2010)

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
por: Ziemssen, Tjalf, et al.
Publicado: (2014)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20‐Year Data from the U.S. Glatiramer Acetate Extension Study
por: Khan, Omar, et al.
Publicado: (2016)

Gadolinium should always be used to assess disease activity in MS – Yes
por: Granziera, Cristina, et al.
Publicado: (2020)

Slowly expanding lesions are a marker of progressive MS – No
por: Arnold, Douglas L, et al.
Publicado: (2021)

The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients – No
por: Tremlett, Helen, et al.
Publicado: (2021)

Challenges in managing a remote monitoring device clinic
por: Harvey, Margaret, et al.
Publicado: (2022)

Assessment of available online educational resources for patients with atrial fibrillation
por: Middeldorp, Melissa E., et al.
Publicado: (2022)

Knowledge of and behaviors toward a gluten-free diet among women at a health sciences university
por: Alkhalifa, Fatima M., et al.
Publicado: (2023)

Ventricular tachycardia and in-hospital mortality in the intensive care unit
por: Prasad, Priya A., et al.
Publicado: (2023)

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
por: Ziemssen, Tjalf, et al.
Publicado: (2014)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1sloe5skl2bpgojpnta1anhsqh